Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
Year-over-year SG&A expense growth
Percentile
P5
Near historical low
vs 5Y Ago
-0.7x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | -41.54% |
| Q2 2025 | -70.64% |
| Q1 2025 | 231.77% |
| Q4 2024 | -4.70% |
| Q3 2024 | -21.32% |
| Q2 2024 | 21.30% |
| Q1 2024 | 28.45% |
| Q4 2023 | -15.50% |
| Q3 2023 | -40.17% |
| Q2 2023 | 22.12% |
| Q1 2023 | -5.63% |
| Q4 2022 | 28.80% |
| Q3 2022 | -4.95% |
| Q2 2022 | 86.34% |
| Q1 2022 | -34.65% |
| Q4 2021 | 33.15% |
| Q3 2021 | 16.61% |
| Q2 2021 | -0.47% |
| Q1 2021 | -4.34% |
| Q4 2020 | -1.59% |
| Q3 2020 | 58.15% |
| Q2 2020 | -24.67% |
| Q1 2020 | 32.59% |
| Q4 2019 | -36.62% |
| Q3 2019 | 69.27% |
| Q2 2019 | -20.98% |
| Q1 2019 | 3.57% |
| Q4 2018 | -32.96% |
| Q3 2018 | 24.63% |
| Q2 2018 | -16.18% |
| Q1 2018 | 40.33% |
| Q4 2017 | -22.47% |
| Q3 2017 | -38.54% |
| Q2 2017 | -14.33% |
| Q1 2017 | 12.91% |
| Q4 2016 | 108.24% |
| Q3 2016 | -49.27% |
| Q2 2016 | 23.99% |
| Q1 2016 | -4.11% |
| Q4 2015 | 28.86% |